MetaADEDB 2.0 @ LMMD
ioxilan
(UUMLTINZBQPNGF-UHFFFAOYSA-N)
Structure
SMILES
OCCNC(=O)c1c(I)c(C(=O)NCC(CO)O)c(c(c1I)N(C(=O)C)CC(CO)O)I
Type(s)
Approved
ATC code(s)
V08AB12
Molecular Formula:
C18H24I3N3O8
Molecular Weight:
791.112
Log P:
-0.2066
Hydrogen Bond Acceptor:
11
Hydrogen Bond Donor:
7
TPSA:
179.66
CAS Number(s):
107793-72-6
Synonym(s)
1.
ioxilan
2.
5-(N-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-N-(2-hydroxyethyl)-N'-(2,3-dihydroxypropyl)isophthalamide
3.
Oxilan
External Link(s)
MeSHC055357
PubChem Compound3743
ChEBI135884
CHEMBLCHEMBL1201075
DrugBankDB09135
DrugCentral1473
KEGGdr:D02161
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1UrticariaFAERS: 33SIDER
US FAERS
2VomitingFAERS: 21SIDER
US FAERS
3NauseaFAERS: 15SIDER
US FAERS
4PruritusFAERS: 15SIDER
US FAERS
5HypersensitivityFAERS: 11SIDER
US FAERS
6SneezingFAERS: 9US FAERS
7Contrast media reactionFAERS: 8US FAERS
8Chest PainFAERS: 6US FAERS
9ErythemaFAERS: 5US FAERS
10HeadacheFAERS: 5SIDER
US FAERS
11Electrocardiogram abnormalFAERS: 4US FAERS
12HypotensionFAERS: 4SIDER
US FAERS
13Atrial FibrillationFAERS: 3SIDER
US FAERS
14DizzinessFAERS: 3SIDER
US FAERS
15Procedural complicationFAERS: 3US FAERS
16BradycardiaFAERS: 2SIDER
US FAERS
17Cardiac ArrestFAERS: 2US FAERS
18CheilitisFAERS: 2US FAERS
19ChillsFAERS: 2SIDER
US FAERS
20ChokingFAERS: 2US FAERS
21DysarthriaFAERS: 2US FAERS
22DysphemiaFAERS: 2US FAERS
23DysphoniaFAERS: 2US FAERS
24HemiparesisFAERS: 2US FAERS
25Post procedural complicationFAERS: 2US FAERS
26Stevens-Johnson SyndromeFAERS: 2US FAERS
27StomatitisFAERS: 2US FAERS
28TremorFAERS: 2US FAERS
29Acute myocardial infarctionFAERS: 1US FAERS
30Airway peak pressure increasedFAERS: 1US FAERS
31Anaphylactic shockFAERS: 1US FAERS
32Angina PectorisFAERS: 1SIDER
US FAERS
33Burning sensationFAERS: 1US FAERS
34Conversion disorderFAERS: 1US FAERS
35CyanosisFAERS: 1US FAERS
36DysgeusiaFAERS: 1SIDER
US FAERS
37Feeling abnormalFAERS: 1US FAERS
38HypercreatininaemiaFAERS: 1US FAERS
39Hyporesponsive to stimuliFAERS: 1US FAERS
40Injection site erythemaFAERS: 1US FAERS
41Injection site extravasationFAERS: 1US FAERS
42Muscle CrampFAERS: 1US FAERS
43Muscle tightnessFAERS: 1US FAERS
44Myocardial InfarctionFAERS: 1US FAERS
45Neck PainFAERS: 1US FAERS
46PainFAERS: 1SIDER
US FAERS
47PresyncopeFAERS: 1US FAERS
48Pulmonary EmbolismFAERS: 1US FAERS
49Reaction to azo-dyesFAERS: 1US FAERS
50Respiratory arrestFAERS: 1US FAERS
51Respiratory distressFAERS: 1US FAERS
52TachycardiaFAERS: 1SIDER
US FAERS
53Throat irritationFAERS: 1US FAERS
54Visual disturbanceFAERS: 1US FAERS
55AmblyopiaSIDER
56AnorexiaSIDER
57AnuriaSIDER
58AstheniaSIDER
59Back PainSIDER
60BronchospasmSIDER
61ConjunctivitisSIDER
62ConstipationSIDER
63DermatitisSIDER
64DyspepsiaSIDER
65DysuriaSIDER
66IleusSIDER
67InfectionSIDER
68Kidney Diseases15926184
19539072
CTD
69Muscle relaxant therapySIDER
70NystagmusSIDER
71PharyngitisSIDER
72Renal Insufficiency18768415CTD
73RhinitisSIDER
74ShockSIDER
75SomnolenceSIDER
76SweatingSIDER
77SyncopeSIDER
78Vasodilation procedureSIDER
79VasodilationSIDER
80VertigoSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.